Show simple item record

dc.contributor.authorBidel, Zen_US
dc.contributor.authorNazarzadeh, Men_US
dc.contributor.authorCanoy, Den_US
dc.contributor.authorCopland, Een_US
dc.contributor.authorGerdts, Een_US
dc.contributor.authorWoodward, Men_US
dc.contributor.authorGupta, AKen_US
dc.contributor.authorReid, CMen_US
dc.contributor.authorCushman, WCen_US
dc.contributor.authorWachtell, Ken_US
dc.contributor.authorTeo, Ken_US
dc.contributor.authorDavis, BRen_US
dc.contributor.authorChalmers, Jen_US
dc.contributor.authorPepine, CJen_US
dc.contributor.authorRahimi, Ken_US
dc.contributor.authorBlood Pressure Lowering Treatment Trialists’ Collaborationen_US
dc.date.accessioned2024-05-13T13:51:51Z
dc.date.issued2023-11en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/96842
dc.description.abstractBACKGROUND: Whether the relative effects of blood pressure (BP)-lowering treatment on cardiovascular outcomes differ by sex, particularly when BP is not substantially elevated, has been uncertain. METHODS: We conducted an individual participant-level data meta-analysis of randomized controlled trials of pharmacological BP lowering. We pooled the data and categorized participants by sex, systolic BP categories in 10-mm Hg increments from <120 to ≥170 mm Hg, and age categories spanning from <55 to ≥85 years. We used fixed-effect one-stage individual participant-level data meta-analyses and applied Cox proportional hazard models, stratified by trial, to analyze the data. RESULTS: We included data from 51 randomized controlled trials involving 358 636 (42% women) participants. Over 4.2 years of median follow-up, a 5-mm Hg reduction in systolic BP decreased the risk of major cardiovascular events both in women and men (hazard ratio [95% CI], 0.92 [0.89-0.95] for women and 0.90 [0.88-0.93] for men; P for interaction, 1). There was no evidence for heterogeneity of relative treatment effects by sex for the major cardiovascular disease, its components, or across the different baseline BP categories (all P for interaction, ≥0.57). The effects in women and men were consistent across age categories and the types of antihypertensive medications (all P for interaction, ≥0.14). CONCLUSIONS: The effects of BP reduction were similar in women and men across all BP and age categories at randomization and with no evidence to suggest that drug classes had differing effects by sex. This study does not substantiate sex-based differences in BP-lowering treatment.en_US
dc.format.extent2293 - 2302en_US
dc.languageengen_US
dc.relation.ispartofHypertensionen_US
dc.subjectblood pressureen_US
dc.subjectcardiovascular diseasesen_US
dc.subjecthypertensionen_US
dc.subjectmeta-analysisen_US
dc.subjectsexen_US
dc.subjectMaleen_US
dc.subjectHumansen_US
dc.subjectFemaleen_US
dc.subjectAged, 80 and overen_US
dc.subjectCardiovascular Diseasesen_US
dc.subjectBlood Pressureen_US
dc.subjectHypertensionen_US
dc.subjectAntihypertensive Agentsen_US
dc.subjectHypotensionen_US
dc.titleSex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis.en_US
dc.typeArticle
dc.identifier.doi10.1161/HYPERTENSIONAHA.123.21496en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37485657en_US
pubs.issue11en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume80en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.funder.project2acae7f5-fd8c-4d20-af2e-447fb9664166en_US


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record